Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a foreign private issuer, has filed a Report on Form 6-K with the United States Securities and Exchange Commission for February 2024, confirming its compliance with the shareholders' equity requirement for continued listing on the Nasdaq Capital Market. The company had previously reported shareholders' equity below the $2.5 million threshold as of October 31, 2023. However, Clearmind Medicine has since increased its shareholders' equity to approximately $7 million, following the exercise of warrants from its March and September 2023 public offerings and a registered direct offering and private placement in January 2024. The company believes it has regained compliance with the Nasdaq's listing requirements and understands that Nasdaq will monitor its ongoing compliance, with potential delisting if non-compliance is found in the next interim report.
Clearmind Medicine Inc., a foreign private issuer, has filed a Report on Form 6-K with the United States Securities and Exchange Commission for February 2024, confirming its compliance with the shareholders' equity requirement for continued listing on the Nasdaq Capital Market. The company had previously reported shareholders' equity below the $2.5 million threshold as of October 31, 2023. However, Clearmind Medicine has since increased its shareholders' equity to approximately $7 million, following the exercise of warrants from its March and September 2023 public offerings and a registered direct offering and private placement in January 2024. The company believes it has regained compliance with the Nasdaq's listing requirements and understands that Nasdaq will monitor its ongoing compliance, with potential delisting if non-compliance is found in the next interim report.
外國私人發行人Clearmind Medicine Inc. 已向美國證券交易委員會提交了2024年2月的6-K表報告，確認其遵守了繼續在納斯達克資本市場上市的股東權益要求。該公司此前曾報告稱，截至2023年10月31日，股東權益低於250萬美元的門檻。但是，繼行使2023年3月和9月的公開發行以及2024年1月的註冊直接發行和私募股權證之後，Clearmind Medicine已將其股東權益增加到約700萬美元。該公司認爲已經恢復了對納斯達克上市要求的遵守，並了解到納斯達克將監督其持續合規情況，如果在下一份中期報告中發現違規行爲，可能會將其退市。
外國私人發行人Clearmind Medicine Inc. 已向美國證券交易委員會提交了2024年2月的6-K表報告，確認其遵守了繼續在納斯達克資本市場上市的股東權益要求。該公司此前曾報告稱，截至2023年10月31日，股東權益低於250萬美元的門檻。但是，繼行使2023年3月和9月的公開發行以及2024年1月的註冊直接發行和私募股權證之後，Clearmind Medicine已將其股東權益增加到約700萬美元。該公司認爲已經恢復了對納斯達克上市要求的遵守，並了解到納斯達克將監督其持續合規情況，如果在下一份中期報告中發現違規行爲，可能會將其退市。
有用
沒用